Brainsway Deep TMS System
Transcranial Magnetic Stimulation System For Obsessive-Compulsive Disorder. 510(k) K183303, from Brainsway , Ltd. (Jerusalem, IL). Product code QCI, class 2.
As of Nov 22, 2026, K183303 is an FDA 510(k) held by Brainsway , Ltd., substantially equivalent on Mar 8, 2019 after 101 days, with no recalls tied to it in FDA's recall database.
- Review time: 101 days
- Recalls: 0
- Cited as a predicate by: 3 devices
The Brainsway Deep Transcranial Magnetic Stimulation System is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder.
- Brainsway Deep Transcranial Magnetic Stimulation (DTMS) SystemDEN170078 · Brainways , Ltd. · Aug 17, 2018
- Brainsway Deep (DTMS) SystemK173540 · Brainsway , Ltd. · May 3, 2018
- BrainsWay Deep TMS SystemK220819 · Brainsway , Ltd. · Aug 26, 2022
- Brainsway Deep (DTMS) SystemK203616 · Brainsway , Ltd. · Apr 16, 2021
- MagVenture TMS Therapy – for treatment of OCD, MagVenture TMS Therapy systemK193006 · Tonica Elektronik A/S · Aug 9, 2020
- Ultimate rTMS for OCD (M-series)K243459 · Brain Ultimate, Inc. · Apr 17, 2025
- BTL-99-OCK230657 · BTL Industries, Inc. · Feb 1, 2024
- CloudTMS Edge for OCDK233742 · Teleemg, LLC · Dec 22, 2023
- OCD MT Cap (85-00397-000)K231350 · Neuronetics · Jun 8, 2023
- CloudTMS for OCDK221129 · Teleemg, LLC · Mar 10, 2023
- NeuroStar Advanced Therapy for adjunctive treatment of OCD, NeuroStar Advanced Therapy System, NeuroStar TMS Therapy…K212289 · Neuronetics, Inc. · May 6, 2022
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Nov 27, 2018
- Review panel
- Neurology
- Regulation
- 21 CFR 882.5802
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files